Keyphrases
Myositis
84%
Idiopathic Inflammatory Myopathies
79%
Dermatomyositis
64%
Autoantibodies
50%
Antisynthetase Syndrome
27%
Interstitial Lung Disease
20%
Inclusion Body Myositis
19%
Muscle Biopsy
18%
Muscle Ultrasound
17%
Reductase
16%
Cancer Risk
14%
Rheumatoid Arthritis
13%
Myopathy
13%
Clinical Features
13%
Anti-MDA5
10%
Long-term Treatment
10%
Severe Disease
10%
Idiopathic Inflammatory Myositis
10%
Clinical Phenotype
9%
Clinical Outcomes
9%
Muscle Disease
9%
Coenzyme A
8%
Intermediary Factors
8%
Intravenous Immunoglobulin (IVIg)
8%
Myositis Autoantibody
7%
Clinical Presentation
7%
Johns Hopkins
7%
Edema
7%
Dysphagia
7%
Large Cohort
6%
Signal Recognition Particle
6%
Inflammatory Arthritis
6%
Ultrasound Emission
6%
Juvenile Myositis
6%
Statins
6%
North America
6%
Clinical Characteristics
6%
Methotrexate
6%
Echogenicity
6%
Clinical Factors
6%
Diagnostic Performance
6%
Tertiary Referral
6%
Activating Enzyme
6%
Interferon Signature
6%
Matrix Protein 2
6%
Unsupervised Novelty Detection
6%
Muscle Involvement
6%
Disease Course
5%
Cutaneous Findings
5%
Human Immunoglobulin
5%
Medicine and Dentistry
Myositis
100%
Dermatomyositis
47%
Myopathy
47%
Disease
41%
Rheumatoid Arthritis
34%
Interstitial Lung Disease
33%
Autoantibodies
27%
Antisynthetase Syndrome
21%
Diagnosis
15%
Inclusion Body Myositis
13%
Magnetic Resonance Imaging
13%
Malignant Neoplasm
12%
Ultrasonography of Muscle
12%
Prevalence
12%
Patient Referral
10%
Oxidoreductase
10%
Immune Checkpoint Inhibitor
9%
Computer Assisted Tomography
9%
Forced Vital Capacity
8%
Nodular Melanoma
8%
Clinical Feature
7%
Immunosuppressive Treatment
7%
Edema
7%
Positron Emission Tomography
7%
Echogenicity
7%
Statin
6%
Population
6%
Symptom
6%
Clinical Trial
6%
Interstitial Nephritis
6%
Glomerulonephritis
5%
Muscle Biopsy
5%
Adverse Event
5%
COVID-19
5%
Immunosuppressive Drug
5%
Tofacitinib
5%
Sarcopenia
5%
Side Effect
5%
Arimoclomol
5%
Lyme Arthritis
5%
microRNA
5%
Alopecia Mucinosa
5%
DLCO
5%
Autoimmune Disease
5%
International Health
5%
Infection
5%
Cancer Diagnosis
5%
Ipilimumab
5%
Avascular Necrosis
5%
Nivolumab
5%
Pharmacology, Toxicology and Pharmaceutical Science
Myositis
79%
Myopathy
39%
Autoantibodies
36%
Disease
33%
Dermatomyositis
31%
Interstitial Lung Disease
25%
Antisynthetase Syndrome
24%
Malignant Neoplasm
16%
Prevalence
12%
Adverse Event
10%
Edema
10%
Rheumatoid Arthritis
10%
Tofacitinib
10%
Clinical Feature
10%
Oxidoreductase
9%
Immunosuppressive Agent
9%
Cohort Study
7%
Ribonucleoprotein
6%
Statin (Protein)
6%
Clinical Trial
6%
Methotrexate
6%
Myocarditis
5%
Weakness
5%
Muscle Weakness
5%
Mitochondrion Antibody
5%
Signal Recognition Particle
5%
Autoimmune Disease
5%
Coronavirinae
5%
Avascular Necrosis
5%
Arimoclomol
5%
Pirfenidone
5%
Infection
5%
Nivolumab
5%
Alopecia
5%
Placebo
5%
Ipilimumab
5%
Tolerability
5%
Side Effect
5%
Muscle Injury
5%
Sjoegren Syndrome
5%
Azathioprine
5%
Human Immunoglobulin
5%
Inclusion Body Myositis
5%